Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisheva Pokroy-Shapira

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Harefuah|August 9, 2017
[IgG4-RELATED DISEASE]Elisheva Pokroy-Shapira, Yair Molad
Clinical Rheumatology|February 19, 2014
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort studyElisheva Pokroy-Shapira, Ilana Gelernter, Yair Molad
Innate Immunity|March 12, 2013
CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and sheddingYair Molad, Elisheva Pokroy-Shapira, Vered Carmon
BMJ Case Reports|August 15, 2012
Capnocytophaga bacteraemia following rituximab treatmentElisheva Pokroy-Shapira, Shachaf Shiber, Yair Molad
Lupus|March 28, 2022
Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcareIftach Sagy, Yarden Cohen, Yehudit Nahum, et al.
Inflammation|July 23, 2013
Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infectionYair Molad, Elisheva Pokroy-Shapira, Tania Kaptzan, et al.
The Israel Medical Association Journal : IMAJ|March 22, 2023
The Effect of Different Ethnic Origins in Israel on the Clinical Manifestations and Outcomes of Systemic Lupus ErythematousYehudit Nahum, Iftach Sagy, Yarden Cohen, et al.
European Journal of Clinical Investigation|April 3, 2015
Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritisYair Molad, Shachaf Ofer-Shiber, Elisheva Pokroy-Shapira, et al.
Rheumatology (Oxford, England)|June 3, 2025
Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from IsraelVictoria Furer, Omer Kersh, Mark Berman, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control studyYair Molad, Mohamad Egbaria, Ana Tovar, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Harefuah|August 9, 2017
[IgG4-RELATED DISEASE]Elisheva Pokroy-Shapira, Yair Molad
Clinical Rheumatology|February 19, 2014
Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort studyElisheva Pokroy-Shapira, Ilana Gelernter, Yair Molad
Innate Immunity|March 12, 2013
CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and sheddingYair Molad, Elisheva Pokroy-Shapira, Vered Carmon
BMJ Case Reports|August 15, 2012
Capnocytophaga bacteraemia following rituximab treatmentElisheva Pokroy-Shapira, Shachaf Shiber, Yair Molad
Lupus|March 28, 2022
Lower socioeconomic status worsens outcome of patients with systemic lupus erythematosus independently of access to healthcareIftach Sagy, Yarden Cohen, Yehudit Nahum, et al.
Inflammation|July 23, 2013
Serum soluble triggering receptor on myeloid cells-1 (sTREM-1) is elevated in systemic lupus erythematosus but does not distinguish between lupus alone and concurrent infectionYair Molad, Elisheva Pokroy-Shapira, Tania Kaptzan, et al.
The Israel Medical Association Journal : IMAJ|March 22, 2023
The Effect of Different Ethnic Origins in Israel on the Clinical Manifestations and Outcomes of Systemic Lupus ErythematousYehudit Nahum, Iftach Sagy, Yarden Cohen, et al.
European Journal of Clinical Investigation|April 3, 2015
Soluble triggering receptor expressed on myeloid cells-1 is a biomarker of anti-CCP-positive, early rheumatoid arthritisYair Molad, Shachaf Ofer-Shiber, Elisheva Pokroy-Shapira, et al.
Rheumatology (Oxford, England)|June 3, 2025
Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from IsraelVictoria Furer, Omer Kersh, Mark Berman, et al.
Clinical and Experimental Rheumatology|January 9, 2023
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control studyYair Molad, Mohamad Egbaria, Ana Tovar, et al.
Pageof 2